Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

outperforms the current standard of care for BCG-naïve, high-risk non-muscle-invasive bladder cancer (HR NMIBC) with a manageable safety profile, primary results from the phase 3 CREST trial show.

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus ...

Given a global shortage of bacillus Calmette-Guérin (BCG) treatment, it has been important to determine whether there are effective alternatives for intermediate-risk non-muscle-invasive bladder ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

The phase 3 CREST trial has been assessing the subcutaneously-administered drug in combination with standard-of-care Bacillus ...